This implies caution and careful assessment of miRNome remodeling should a truncated Dicer variant be considered a therapeutic agent, such as the proposed gene therapy for Dicer deficiency in macular degeneration based on an N-terminally truncated Dicer variant termed OptiDicer (Wright et al., 2020). Here, DICER1 is linked to macular degeneration.